Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Signals Willingness To Grant Regulatory Flexibility For Cell and Gene Therapy Products In CMC Reviews

Executive Summary

US FDA official says that the complexities involved in producing cell and gene therapies necessitate a “new manufacturing paradigm” in evaluating biologics license applications. For such therapies, the agency is willing to grant regulatory flexibility in certain areas of its chemistry, manufacturing and controls review.

 

Advertisement

Related Content

Cell Therapies: US FDA Asked To Clarify Development Standards For Early-Phase Trials
Regenerative Medicine Therapies: Manufacturing Changes May Not Impact RMAT Designation
Shutdown Bite Tightens At US FDA, But Gene Therapy To Get 50 More Reviewers
CBER Implements Pre-Clinical Meeting Program For Biologics, Gene Therapy Sponsors
Woodcock, Califf Give Thumbs Up To Certain 21st Century Cures Provisions

Topics

Advertisement
UsernamePublicRestriction

Register

PS125450

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel